REDWOOD CITY, Calif. & TOKYO--(BUSINESS WIRE)--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, announced today that the ...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a leader in diagnostic and therapeutic pulmonary device technologies, announced today that its Zephyr® Valve has received positive coverage ...
VIENNA — Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE ...
SILVER SPRING, Md., June 29, 2018 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved a new device, the Zephyr Endobronchial Valve (Zephyr Valve), intended to treat ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved the Zephyr endobronchial valve for treating breathing difficulty associated with severe ...
The Zephyr valve is a device that can improve breathing in people with emphysema, one of the two most common types of chronic obstructive pulmonary disease (COPD). The valve received approval by the ...
In late March, physicians at the University of Alabama at Birmingham carefully threaded a one-way valve the size of a black-eyed pea into the lower lobe of Dennis Bullock's left lung. Bullock, a ...
The U.S. Food and Drug Administration today approved a new device, the Zephyr Endobronchial Valve (Zephyr Valve), intended to treat breathing difficulty associated with severe emphysema. "Treatment ...
The US Food and Drug Administration (FDA) has approved the Zephyr Endobronchial Valve (Pulmonx Corp) to treat breathing difficulty associated with severe emphysema. "Treatment options are limited for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results